Semaglutide, originally developed for the treatment of diabetes, was approved by the FDA on 4 June 2021 as a weight-loss medication due to its ability to activate glucagon-like peptide-1 receptor (GLP1R) in the central nervous system [3], reducing food intake and promoting weight loss [4]. The gene discussed is GLP1R; the disease is diabetes mellitus.